Circulating markers of endothelial dysfunction in type 2 diabetic patients with microalbuminuria

1. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases orking Group on Cardiovascular Complications of type 1 diabetes mellitus. Circulation. 2005; 111:3489-93.10.1161/CIRCULATIONAHA.104.529651Open DOISearch in Google Scholar

2. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet. 1998; 2:530-3.Search in Google Scholar

3. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol. 2007; 27:554-64.10.1159/000107758Open DOISearch in Google Scholar

4. Ruggeri ZM, Ware J. Von Willebrand factor. Faseb J. 1993; 7:308-16.10.1096/fasebj.7.2.8440408Search in Google Scholar

5. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, Den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin dependent diabetes mellitus. Lancet. 1992; 340:319-23.10.1016/0140-6736(92)91401-SOpen DOISearch in Google Scholar

6. Stehouwer CDA, Fischer HRA, Kuijk AW R, Polak BCP, Donker AJM. Endothelial dysfunction precedes development of micro-albuminuria in IDDM. Diabetes. 1995; 44:561-4.10.2337/diab.44.5.561Open DOISearch in Google Scholar

7. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989; 264:4743-6.10.1016/S0021-9258(18)83649-3Search in Google Scholar

8. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest. 1985; 76: 2178-81.10.1172/JCI1122254243393001144Open DOISearch in Google Scholar

9. Coen AD, Stehouwer A. Endothelial dysfunction in diabetes nephropathy: state of the art and potential significance for non diabetic renal disease. Nephrol Dial Transplant. 2004; 19:778e81.10.1093/ndt/gfh01515031329Search in Google Scholar

10. Loreth RM, Seus CH, Berger HH, Albert FW. Plasma thrombomodulin concentrations in healthy persons depends on age and sex. Annals of hematology. 1997; 74 (Suppl.II):A89.Search in Google Scholar

11. Ingerslev J. Sensitive ELISA for von Willebrand factor (vWF:ag).Scand J Clin Lab Invest. 1987; 47:143-9.10.3109/00365518709168882Open DOISearch in Google Scholar

12. Kathryn GB, Wing-Sun C, Victor H G, Christine M, Richar B, Karen SL. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002; 25:1055-9.10.2337/diacare.25.6.105512032114Open DOISearch in Google Scholar

13. Bashyam MM. Microalbuminuria in NIDDM. Diabetes Care. 1993; 16:634-5.10.2337/diacare.16.4.634Open DOISearch in Google Scholar

14. Richmond W. “Determination of cholesterol” cited in instruction of “Bio-Merieux”. Clin Chem. 1973;19: 1350-6.10.1093/clinchem/19.12.1350Search in Google Scholar

15. Henary RJ, Connon DC, Winkelman JW. Clinical Chemistry Principle and Techniques. New York: Harber & Raw; 1974.Search in Google Scholar

16. Fossati, P, Prencipe L. Serum triglycerides determined color metrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982; 298:2077-80.10.1093/clinchem/28.10.2077Search in Google Scholar

17. Committee on the enzymes of the Scandinavian Society for Clinical Chemistry and Clinical physiology. Recommended methods for the determination of four enzymes in blood. Scand. J. Clin. Lab. Invest. 1974; 3: 291-309.Search in Google Scholar

18. Karasek D, vaverkova H, Halenka M, Slarik L, Novotny D.Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. Thrombo Res. 2009; 123:466-75.10.1016/j.thromres.2008.02.011Open DOISearch in Google Scholar

19. Blann A. Assessment of endothelial dysfunction: Focus on atherothrombotic disease. Pathofisiol Haemost Thromb. 2003; 33:256-61.10.1159/000083811Search in Google Scholar

20. Hirano T, Ookubob K, Kashiwazakia K, Tajima H,Yoshino G, Adachi M. Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clinica Chimica Acta. 2000; 299:65-75.10.1016/S0009-8981(00)00274-6Open DOISearch in Google Scholar

21. Viswanathan V, Snehalatha C, Nair MB, Ramachandran A. Markers of endothelial dysfunction in hyperglycaemic Asian Indian subjects, J. Diabet. Complications. 2004; 18:47-52.10.1016/S1056-8727(03)00037-0Open DOISearch in Google Scholar

22. Jensen T. Increased plasma level of von Willebrand factor in Type1 (insulin-dependent) diabetic patients with incipient nephropathy. Br Med J. 1989; 298:27-8.10.1136/bmj.298.6665.27-aSearch in Google Scholar

23. Shimano H, Takahashi K, Kawakami M. Elevated serum and urinary thrombomodulin levels in patients with non-insulin-dependent diabetes mellitus. Clin Chim Acta. 1994; 25:89-96.10.1016/0009-8981(94)90036-1Open DOISearch in Google Scholar

24. Rinno H, Kuramoto T, Iijima T, Yagame M. Tomino E. Measurement of soluble thrombomodulin in sera from various clinical stages of diabetic nephropathy. J Clin Lab Anal. 1996; 10:119-24.10.1002/(SICI)1098-2825(1996)10:3<119::AID-JCLA1>3.0.CO;2-6Open DOISearch in Google Scholar

25. Zimmermann J, Schramm L, Wanner C. Hemorheology, plasma protein composition and Von Willebrand factor in type I diabetic nephropathy. Clin Nephrol. 1996; 46:230-6.Search in Google Scholar

26. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation. 2005; 112:32-8.10.1161/CIRCULATIONAHA.104.520130Open DOISearch in Google Scholar

27. Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia, Diabetes Care. 2000; 23:1395-400.10.2337/diacare.23.9.1395Open DOISearch in Google Scholar

28. Ibrahim HA, Melig AA. El-I Abdel-Hamid, Elhendy MA. Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus, Med Sci Monit. 2004; 10:85-9.Search in Google Scholar

29. Giancarlo DM, Maria CB, Oriana L, Arianna M, Rosalba C, Alessandra G, et al. Endothelial dysfunction and oxidative stress in type 1 and type 2 diabetic patients without clinical macrovascular complications. Diabetes Res and Clin pract. 2008; 79:337-42.10.1016/j.diabres.2007.09.005Search in Google Scholar

30. Takanashi K, Inukai T. Insulin resistance and changes in blood coagulation-fibrinolysis system after a glucose clamp technique in patients with type 2 diabetes mellitus. J Med. 2000; 31:45-9.Search in Google Scholar

31. Wu KK. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol. 2003; 14:373-5.10.1097/00041433-200308000-00006Open DOISearch in Google Scholar

32. Soichiro U, Katuhiro G, Hiroshi H. Separation and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. Thromb Res. 2001; 104:325-32.10.1016/S0049-3848(01)00358-9Open DOISearch in Google Scholar

33. Okumura K, Aso Y. High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism. 2003; 52:1517-2210.1016/S0026-0495(03)00324-XOpen DOISearch in Google Scholar

34. Ross R. Atherosclerosis; an inflammatory disease. N Engl J Med. 1999; 340:115-26.10.1056/NEJM199901143400207Search in Google Scholar

35. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, et al. Soluble thrombomodulin as a predictor coronary heart disease and symptomless carotid artery atherosclerosis in the atherosclerosis risk in communities (ARIC) study: a case-cohort study. Lancet. 1999; 353:1729-34.10.1016/S0140-6736(98)09057-6Search in Google Scholar

36. Hayakawa T, Shouza A, Nishikawa M. Effects of Beraprost and Cilostazoland renal function on serum TM levels in diabetic patients. Arzneimittelforschung. 2000; 50:535-9.Search in Google Scholar

37. Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol. 2001; 86:5491-7.10.1210/jcem.86.11.803511701727Open DOISearch in Google Scholar

38. Balakumar P, Chakkarwar VA, Krishan P, Manjeet S. Vascular endothelial dysfunction: A tug of war in diabetic nephropathy? Biomedicine & Pharmacotherapy. 2009; 63:171-9.10.1016/j.biopha.2008.08.00818823739Open DOISearch in Google Scholar

39. Mezzano D, Tagle R, Pais E. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res. 1997; 88: 465-72.10.1016/S0049-3848(97)00280-6Open DOISearch in Google Scholar

40. Hirano T, Ookubob K, Kashiwazakia K, Tajima H, Yoshino G, Adachi M. Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clinica Chimica Acta. 2000; 299:65-75 10.1016/S0009-8981(00)00274-6Open DOISearch in Google Scholar